StockNews.com Initiates Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)

StockNews.com assumed coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) in a research report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Bellicum Pharmaceuticals Stock Performance

Bellicum Pharmaceuticals stock opened at $1.03 on Monday. The company has a market cap of $8.89 million, a P/E ratio of -2.06 and a beta of 1.25. Bellicum Pharmaceuticals has a one year low of $0.93 and a one year high of $2.20. The business has a fifty day moving average of $1.10 and a two-hundred day moving average of $1.23.

About Bellicum Pharmaceuticals

(Get Rating)

Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.

Read More

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.